Intranasal mucoadhesive microemulsion of tacrine to improve brain targeting

Alzheimer Disease and Associated Disorders

Volumn 22, Issue 2, 2008, Pages 116-124

  Jogani, Viral V ^a   Shah, Pranav J ^a   Mishra, Pushpa ^b   Mishra, Anil Kumar ^b   Misra, Ambikanandan R ^a  

^a M S UNIVERSITY OF BARODA   (India)

^b INSTITUTE OF NUCLEAR MEDICINE AND ALLIED SCIENCES   (India)

Author keywords

Alzheimer disease; Biodistribution; Brain targeting; Intranasal; Morris water maze test; Mucoadhesive microemulsion; Tacrine

Indexed keywords

PERTECHNETIC ACID TC 99M; SCOPOLAMINE BUTYL BROMIDE; TACRINE; CHOLINESTERASE INHIBITOR; TISSUE ADHESIVE;

AMNESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN SCINTISCANNING; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EFFECT; DRUG FORMULATION; DRUG TARGETING; DRUG TRANSPORT; GAMMA SCINTIGRAPHY; ISOTOPE LABELING; MICROEMULSION; MOUSE; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; RABBIT; TITRIMETRY; ALZHEIMER DISEASE; ANIMAL; BRAIN; COMPUTER ASSISTED EMISSION TOMOGRAPHY; EMULSION; HUMAN; INTRANASAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; MUCOSA; NOSE MUCOSA; REVIEW; ULTRASTRUCTURE;

ADMINISTRATION, INTRANASAL; ALZHEIMER DISEASE; ANIMALS; BRAIN; CHOLINESTERASE INHIBITORS; EMULSIONS; HUMANS; INJECTIONS, INTRAVENOUS; MICE; MUCOUS MEMBRANE; NASAL MUCOSA; RABBITS; TACRINE; TISSUE ADHESIVES; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 46249130079     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: 10.1097/WAD.0b013e318157205b     Document Type: Article

References (61)

1. Marx J. Alzheimer's research moves to mice. Science. 1991;253: 266-267.
2. Giacobini E. Pharmacotherapy of Alzheimer's disease: new drugs and novel therapy. In: Corain B, Iqbal K, Nicolini M, et al, eds. Alzheimer's Disease: Advances in Clinical and Basic Research. New York: Wiley; 1993:529-538.
3. Small GW. Tacrine for treating Alzheimer's disease. J Am Med Assoc. 1992;268:2564-2565.
4. Davis KL, Powchik P. Tacrine. Lancet. 1995;345:625-630.
5. Giacobini E. Cholinesterase inhibitors for Alzheimer's disease therapy: from tacrine to future applications. Neurochem Int. 1998; 32:413-419.
6. Telting-Diaz M, Lunte CE. Distribution of tacrine across the bloodbrain barrier in awake, free moving rats using in vivo microdialysis sampling. Pharm Res. 1993;10:44-48.
7. Hartvig P, Askmark H, Aquilonius SM, et al. Clinical pharmacokinetics of intravenous and oral 9-amino-l,2,3,4-tetrahydroacridine, tacrine. Eur J Clin Pharmacol. 1990;38:259-263.
8. Lou G, Montgomery PR, Sitar DS. Bioavailability and pharmacokinetic disposition of tacrine in elderly patients with Alzheimer's disease. J Psychiatry Neurosci. 1996;21:334-339.
9. O'Brien JT, Eagger S, Levy R. Effects of tetrahydroaminoacridine on liver function in patients with Alzheimer's disease. Age Ageing. 1991;20:129-131.
10. Farlow M, Gracon SI, Hershey LA, et al. A controlled trial of tacrine in Alzheimer's disease. J Am Med Assoc. 1992;268: 2523-2529.
11. Sathyan G, Ritschel WA, Hussain AS. Transdermal delivery of tacrine: I, Identification of suitable delivery vehicle. Int J Pharma. 1995;114:75-83.
12. Abramowicz M. Tacrine for Alzheimer's disease. Med Lett Drugs Ther. 1993;35:87-88.
13. Qizilbash N, Birks J, Lopez-Arrieta J, et al. Tacrine for Alzheimer's disease. Cochrane Database of Syst Rev. 2000;3:CD000202.
14. Yang Q, Williams D, Owusu-Ababio G, et al. Controlled release tacrine delivery system for the treatment of Alzheimer's disease. Drug Deliv. 2001;8:93-98.
15. Frey WH II. Bypassing the blood-brain barrier to deliver therapeutic agents to the brain and spinal cord. Drug Deliv Technol. 2002;2:46-49.
16. Illum L. Is nose-to-brain transport of drugs in man a reality? J Pharm Pharmacol. 2004;56:3-17.
17. Vyas TK, Shahiwala A, Misra A, et al. Intranasal drug delivery for central nervous system. Curr Drug Deliv. 2005;2:165-175.
18. Dragphia R, Caillaud C, Manicom R, et al. Gene delivery into the central nervous system by nasal instillation in rats. Gene Ther. 1995;2:418-423.
19. Wermling DP, Miller JP, Archer SM, et al. Bioavailability and pharmacokinetics of lorazepam after intranasal, intravenous and intramuscular administration. J Clin Pharmacol. 2001;41:1225-1231.
20. Liu XF, Fawcett JR, Thorne RG, et al. Intranasal administration of Insulin-like growth factor-I bypasses the blood-brain barrier and protects against focal cerebral ischemic damage. J Neurol Sci. 2001;187:91-97.
21. Dorman DC, Brenneman KA, McElveen AM, et al. Olfactory transport: a direct route of delivery of inhaled manganese phosphate to rat brain. J Toxicol Environ Health A. 2002;65:1493-1511.
22. Behl CR, Pimplaskar HK, Sileno AP, et al. Effects of physicochemical properties and other factors on systemic nasal delivery. Adv Drug Deliv Rev. 1998;29:89-116.
23. Illum L. Transport of drugs from nasal cavity to central nervous system. Eur J Pharm Sci. 2000;11:1-18.
24. Graff CL, Pollack GM. Nasal drug delivery: potential for targeted central nervous system delivery. J Pharm Sci. 2005;94:1187-1195.
25. Lawrence MJ, Rees GD. Microemulsion-based media as novel drug delivery systems. Adv Drug Deliv Rev. 2000;45:89-121.
26. Ugwoke MI, Verbeke N, Kinget R. The biopharmaceutical aspects of nasal mucoadhesive drug delivery. J Pharm Pharmacol. 2001; 53:3-21.
27. Praspari S, Parkpoom T. Enhancing effect of chitosan on nasal absorption of salmon calcitonin in rats: comparison with hydroxypropyl and dimethyl-beta-cyclodextrins. Int J Pharm. 2003;257: 15-22.
28. Alpar HO, Somavarapu S, Atuah KN, et al. Biodegradable mucoadhesive particulates for nasal and pulmonary antigen and DNA delivery. Adv Drug Deliv Rev. 2005;57:411-430.
29. Gavini E, Rassu G, Sanna V, et al. Mucoadhesive microspheres for nasal administration of an antiemetic drug, metoclopramide: in-vitro/ex-vivo studies. J Pharm Pharmacol. 2005;57:287-294.
30. Vyas TK, Sharma RK, Misra A, et al. Intranasal mucoadhesive microemulsion of zolmitriptan: preliminary studies on braintargeting. J Drug Target. 2005;13:317-324.
31. Vyas TK, Sharma RK, Misra A, et al. Preliminary brain targeting studies of intranasal mucoadhesive microemulsions of sumatriptan. AAPS Pharm Sci Tech. 2006;7:Article 8.
32. Vyas TK, Sharma RK, Misra A, et al. Intranasal mucoadhesive microemulsions of clonazepam: preliminary studies on brain targeting. J Pharm Sci. 2006;95:570-580.
33. Roland I, Piel G, Delattre L, et al. Systemic characterization of oil-in-water emulsions for formulation design. Int J Pharm. 2003; 263:85-94.
34. Eckelman WC. Radiolabeling with technetium-99m to study highcapacity and low-capacity biochemical systems. Eur J Nucl Med. 1995;22:249-263.
35. 99mTc labeled Photosan-3, a haematoporphyrin derivative, as a potential radiopharmaceutical for tumor scintigraphy. Nucl Med Biol. 2000;27: 419-426.
36. Mishra AK, Panwar P, Hosono M, et al. A new bifunctional chelating agent conjugated with monoclonal antibody and labeled with technetium-99m for targeted scintigraphy: 6-(4-isothiocyanatobenzyl)-5,7-dioxo-1,11-(carboxymethyl)-1,4,8, 11-tetraazacyclotridecane. J Drug Target. 2004;12:559-567.
37. Saha GB. Methods of radiolabeling. In: Saha GB, ed. Physics and Radiobiology of Nuclear Medicine. New York: Springer-NewVerlag; 1993:100-106.
38. Saha GB. Fundamentals of Nuclear Pharmacy. 5th ed. New York: Springer-Verlag; 2005.
39. Theobald AE. Theory and practice. In: Sampson CB, ed. Text Book of Radio Pharmacy. New York: Gorden and Breach; 1990:127-128.
40. 99mTc labeling of monoclonal antibodies: radiolabeling and in-vitro stability. Int J Radiat Appl Instrum. 1991;18:695-703.
41. Chow HS, Chen Z, Matsuura GT. Direct transport of cocaine from the nasal cavity to brain following intranasal cocaine administration in rats. J Pharm Sci. 1999;88:754-758.
42. Zhang Q, Jiang X, Xiang W, et al. Preparation of nimodipineloaded microemulsion for intranasal delivery and evaluation of the targeting efficiency to brain. Int J Pharm. 2004;275:85-96.
43. Thorne RG, Pronk GJ, Padmanabhan V, et al. Delivery of insulinlike growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience. 2004;127:481-496.
44. 99mTc and in vivo localization following intracerebral injection in to normal and glioma bearing rats. Bioconjug Chem. 1997;8:289-295.
45. Morris RG. Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Method. 1984;11:47-60.
46. Lee KY, Jeong EJ, Lee HS, et al. Acteoside of Callicarpa dichotoma attenuates scopolamine-induced memory impairments. Biol Pharm Bull. 2006;29:71-74.
47. Espinosa-Jimenez M, Padilla-Weigand R, Ontiverous-Ortega A, et al. Interpretation of colloidal dyeing of polyester fabrics pretreated with ethyl xanthogenate in terms of zeta potential and surface free energy balance. J Colloid Interface Sci. 2003;265: 227-233.
48. Block LH. Pharmaceutical emulsions and microemulsions. In: Lieberman HA, Rieger MM, Banker GS, eds. Pharmaceutical Dosage Forms. Vol 1. 2nd ed. 2001:47-110 (Revised and Expanded).
49. Nash RA. Pharmaceutical suspensions. In: Lieberman HA, Rieger MM, Banker GS, eds. Pharmaceutical Dosage Forms. Vol 1. 2nd ed. 2001:1-47 (Revised and Expanded).
50. Pietrowky R, Thieman A, Kern W, et al. A nose-brain pathway for psychotropic peptides evidence from a brain evolved potential study with cholecystokinin. Psychoneuroendocrinology. 1996;21: 559-572.
51. Sakane T, Yamashita S, Yata N, et al. Transnasal delivery of 5-fluorouracil to the brain in the rat. J Drug Target. 1999;7: 233-240.
52. Fehm HL, Perras B, Smolnik R, et al. Manipulating neuropeptidergic pathway in humans: a novel approach to neuropharmacology. Eur J Pharmacol. 2000;405:43-54.
53. Quay SC. Successful delivery of apomorphine to the brain following intranasal administration demonstrated in clinical study. PR Newswire. 2001.
54. Lianli L, Nandi I, Kim KH. Development of an ethyl laurate-based microemulsion for rapid-onset intranasal delivery of diazepam. Int J Pharm. 2002;237:77-85.
55. Kim SR, Kang SY, Lee KY, et al. Anti-amnestic activity of E-pmethoxycinnamic acid from Scrophularia buergeriana. Cogn Brain Res. 2003;17:454-461.
56. Murray TK, Cross AJ, Green AR. Reversal by tetrahydroaminoa-cridine of scopolamine-induced memory and performance deficits in rats. Psychopharmacology. 1991;105:134-136.
57. Rupniak NMJ, Tye SJ, Field MJ. Enhanced performance of spatial and visual recognition memory tasks by the selective acetylcholinesterase inhibitor E2020 in rhesus monkeys. Psychopharmacology. 1997;131:406-410.
58. Ebert U, Oertel R, Wesnes KA, et al. Effects of physostigmine on scopolamine-induced changes in quantitative electroencephalogram and cognitive performance. Hum Psychopharmacol: Clin Exp. 1998;13: 199-210.
59. Benedict C, Hallschmid M, Hatke A, et al. Intranasal insulin improves memory in humans. Psychoneuroendocrinology. 2004;29: 1326-1334.
60. Benedict C, Hallschmid M, Schmitz K, et al. Intranasal insulin improves memory in humans: superiority of insulin aspart. Neuropsychopharmacology. 2007;32:239-243.
61. Reger MA, Watson GS, Frey WH II, et al. Effects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE genotype. Neurobiol Aging. 2006;27:451-458.